BR112022008321A2 - Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas - Google Patents
Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticasInfo
- Publication number
- BR112022008321A2 BR112022008321A2 BR112022008321A BR112022008321A BR112022008321A2 BR 112022008321 A2 BR112022008321 A2 BR 112022008321A2 BR 112022008321 A BR112022008321 A BR 112022008321A BR 112022008321 A BR112022008321 A BR 112022008321A BR 112022008321 A2 BR112022008321 A2 BR 112022008321A2
- Authority
- BR
- Brazil
- Prior art keywords
- repolarize
- polypeptide
- treat
- methods
- macrotodelude
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Recrystallisation Techniques (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- External Artificial Organs (AREA)
Abstract
POLIPEPTÍDEOS ISOLADOS, POLIPEPTÍDEO, ÁCIDO NUCLEICO ISOLADO, VETOR DE EXPRESSÃO, CÉLULA HOSPEDEIRA, MÉTODOS PARA PRODUZIR UM POLIPEPTÍDEO, PARA TRATAR CÂNCER, PARA TRATAR UMA DOENÇA NEUROLÓGICA OU NEURODEGENERATIVA, PARA REPOLARIZAR CÉLULAS SUPRESSORAS, PARA REPOLARIZAR MACRÓFAGOS DE TUMOR E PARA ATIVAR CÉLULAS MIELOIDES EM UM SUJEITO E COMPOSIÇÕES FARMACÊUTICAS. A presente divulgação, em geral, se refere a ECDs Siglec-9 e moléculas de fusão de ECD Siglec-9, e a métodos para tratamento usando ECDs Siglec-9 e moléculas de fusão de ECD Siglec-9.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962930227P | 2019-11-04 | 2019-11-04 | |
US202063014940P | 2020-04-24 | 2020-04-24 | |
US202063092753P | 2020-10-16 | 2020-10-16 | |
PCT/US2020/058687 WO2021091885A2 (en) | 2019-11-04 | 2020-11-03 | Siglec-9 ecd fusion molecules and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008321A2 true BR112022008321A2 (pt) | 2022-07-26 |
Family
ID=73598983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008321A BR112022008321A2 (pt) | 2019-11-04 | 2020-11-03 | Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas |
Country Status (17)
Country | Link |
---|---|
US (1) | US11987612B2 (pt) |
EP (1) | EP4055031A2 (pt) |
JP (1) | JP2022553571A (pt) |
KR (1) | KR20220092918A (pt) |
CN (1) | CN114667298A (pt) |
AU (1) | AU2020378251A1 (pt) |
BR (1) | BR112022008321A2 (pt) |
CA (1) | CA3155345A1 (pt) |
CL (1) | CL2022001130A1 (pt) |
CO (1) | CO2022005587A2 (pt) |
CR (1) | CR20220244A (pt) |
EC (1) | ECSP22044316A (pt) |
IL (1) | IL292499A (pt) |
MX (1) | MX2022005376A (pt) |
PE (1) | PE20221271A1 (pt) |
TW (1) | TW202132329A (pt) |
WO (1) | WO2021091885A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023522251A (ja) | 2020-04-24 | 2023-05-29 | バイエル・アクチエンゲゼルシヤフト | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
WO2024102635A1 (en) * | 2022-11-07 | 2024-05-16 | Alector Llc | Uses of siglec-9 ecd fusion molecules in cancer treatment |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
GB0521991D0 (en) | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
US20070244038A1 (en) | 2006-04-12 | 2007-10-18 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
AU2012355435A1 (en) | 2011-12-21 | 2014-07-17 | Amgen Inc. | Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor |
JP6403062B2 (ja) | 2012-12-21 | 2018-10-10 | 国立大学法人徳島大学 | 組織修復活性組成物及びその利用 |
WO2014120642A1 (en) | 2013-01-30 | 2014-08-07 | The General Hospital Corporation | Diagnosis and treatment of hepatorenal syndrome |
WO2016038064A1 (en) | 2014-09-10 | 2016-03-17 | Innate Pharma | Cross reactive siglec antibodies |
KR102434330B1 (ko) | 2015-05-01 | 2022-08-22 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 글리칸 의존성 면역치료 분자 |
CA3003458A1 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
US10634656B2 (en) | 2015-10-30 | 2020-04-28 | Hach Company | Storage stable standards for aqueous chlorine analysis |
AU2016354924A1 (en) * | 2015-11-17 | 2018-06-21 | Innate Pharma | Siglec-10 antibodies |
AU2017207807A1 (en) | 2016-01-12 | 2018-07-12 | Palleon Pharmaceuticals Inc. | Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer |
US11078274B2 (en) | 2016-03-08 | 2021-08-03 | Innate Pharma | Siglec neutralizing antibodies |
GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King's College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
CA3026588A1 (en) | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
WO2019011855A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | ANTIBODIES NEUTRALIZING SIGLEC-9 |
EP3652207A1 (en) | 2017-07-10 | 2020-05-20 | Innate Pharma | Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer |
EP3802582A4 (en) | 2018-06-07 | 2022-06-15 | Palleon Pharmaceuticals Inc. | MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER |
KR20210040948A (ko) | 2018-06-29 | 2021-04-14 | 베르조 테라퓨틱스, 아이엔씨. | 단핵구 및 대식세포의 염증성 표현형을 조절하기 위한 조성물 및 방법, 그리고 이의 면역요법 용도 |
KR20210070301A (ko) | 2018-10-02 | 2021-06-14 | 오비아이 파머 인코퍼레이티드 | 종양 치료제와 조합한 항-ssea-4 항체를 사용하는 병용 요법 |
US20220211831A1 (en) | 2019-04-17 | 2022-07-07 | Bar-Ilan University | Siglec-based chimeric polypeptides and uses thereof |
JP2022535417A (ja) | 2019-06-04 | 2022-08-08 | ヴェルソー セラピューティクス, インコーポレイテッド | 骨髄細胞炎症性表現型を調節するための抗siglec-9組成物及び方法、ならびにその使用 |
US20220283165A1 (en) | 2019-07-12 | 2022-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Enhancing Immunogenicity of Cancers |
-
2020
- 2020-11-03 AU AU2020378251A patent/AU2020378251A1/en active Pending
- 2020-11-03 US US17/088,149 patent/US11987612B2/en active Active
- 2020-11-03 WO PCT/US2020/058687 patent/WO2021091885A2/en unknown
- 2020-11-03 KR KR1020227017802A patent/KR20220092918A/ko unknown
- 2020-11-03 CA CA3155345A patent/CA3155345A1/en active Pending
- 2020-11-03 EP EP20816024.2A patent/EP4055031A2/en active Pending
- 2020-11-03 TW TW109138156A patent/TW202132329A/zh unknown
- 2020-11-03 CR CR20220244A patent/CR20220244A/es unknown
- 2020-11-03 MX MX2022005376A patent/MX2022005376A/es unknown
- 2020-11-03 PE PE2022000710A patent/PE20221271A1/es unknown
- 2020-11-03 JP JP2022524955A patent/JP2022553571A/ja active Pending
- 2020-11-03 BR BR112022008321A patent/BR112022008321A2/pt unknown
- 2020-11-03 CN CN202080076354.8A patent/CN114667298A/zh active Pending
-
2022
- 2022-04-25 IL IL292499A patent/IL292499A/en unknown
- 2022-04-29 CO CONC2022/0005587A patent/CO2022005587A2/es unknown
- 2022-05-02 CL CL2022001130A patent/CL2022001130A1/es unknown
- 2022-06-02 EC ECSENADI202244316A patent/ECSP22044316A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022001130A1 (es) | 2023-02-24 |
US20210284710A1 (en) | 2021-09-16 |
ECSP22044316A (es) | 2022-07-29 |
CN114667298A (zh) | 2022-06-24 |
KR20220092918A (ko) | 2022-07-04 |
MX2022005376A (es) | 2022-05-19 |
US11987612B2 (en) | 2024-05-21 |
JP2022553571A (ja) | 2022-12-23 |
PE20221271A1 (es) | 2022-09-01 |
TW202132329A (zh) | 2021-09-01 |
CR20220244A (es) | 2022-06-28 |
IL292499A (en) | 2022-06-01 |
CO2022005587A2 (es) | 2022-07-29 |
CA3155345A1 (en) | 2021-05-14 |
WO2021091885A3 (en) | 2021-06-17 |
EP4055031A2 (en) | 2022-09-14 |
WO2021091885A2 (en) | 2021-05-14 |
AU2020378251A1 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210154B1 (ar) | مثبطات kif18a | |
MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
MX2021007104A (es) | Inhibidores de kif18a. | |
CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
EA201891092A1 (ru) | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках | |
MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
EA202091566A1 (ru) | Содержащая нуклеиновую кислоту липидная наночастица и ее применение | |
EA202090817A1 (ru) | Триспецифические белки и способы их применения | |
MX2022001181A (es) | Inhibidores de kif18a. | |
WO2018183888A3 (en) | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling | |
MX2019010848A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
BR112017020445A2 (pt) | polipeptídeo de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de um polipeptídeo de fusão, uso do polipeptídeo de fusão, método para ativar as vias de sinalização, método para coestimular células, método para induzir a proliferação de linfócitos e método para direcionar o agrupamento de cd137 | |
BR112022008321A2 (pt) | Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas | |
BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
BR112022011854A2 (pt) | Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção | |
AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
MX2020012107A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo |